Nomura raises Ranbaxy to buy on Sun takeover

Tags: Companies
Ranbaxy Laboratories gains 0.2 percent to 481 rupees after Nomura upgrades the stock to "buy" from "reduce" and raises its target price to 543 rupees from 321 rupees on the back of its takeover by Sun Pharmaceutical Industries.

Although Nomura says Ranbaxy shares look expensive on valuation, it notes the stock should now move in tandem with Sun Pharma, hence the steep increase in its target price.

Ranbaxy shares are trading well above the Sun offer that valued the takeover target at 457 rupees apiece.

Sun is trading 0.1 percent higher at 637.30 rupees.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • RBI has been wise to retain policy rates

    The Reserve Bank of India has been wise to retain policy rates in its latest money policy announcement.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Nigavekar

Education domain must be autonomous

Few issues in the higher education domain exist despite numerous ...

Rajgopal Nidamboor

Can we modify our emotional bearings?

We are not always a replica of our thoughts, emotions ...

Gautam Gupta

French fashion icon Gaultier’s pret goodbye

With Gaultier gone, the world of international prêt will never ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture